Role of vancomycin in the treatment of bacteraemia and meningitis caused by Elizabethkingia meningoseptica

Shio Shin Jean, Tai Chin Hsieh, Yong Zhong Ning, Po Ren Hsueh

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Elizabethkingia meningoseptica, a Gram-negative pathogen once deemed clinically insignificant, tends to cause infections among low-birth-weight infants and immunocompromised patients. Previously, vancomycin was reported to cure several patients with bacteraemia caused by E. meningoseptica. Nevertheless, some laboratory investigations also showed considerable discordance between in vitro vancomycin susceptibility results obtained by the disk diffusion and broth microdilution methods against clinical E. meningoseptica isolates as determined using the criteria for staphylococci recommended by the Clinical and Laboratory Standards Institute (CLSI). In this review, the PubMed database (1960-2017) was searched for studies that reported mainly cases with E. meningoseptica bacteraemia or meningitis treated with vancomycin alone or with regimens that included vancomycin. In addition, the in vitro synergy between vancomycin and other agents against isolates of E. meningoseptica was reviewed. Elizabethkingia meningoseptica bacteraemia appears not to universally respond to intravenous (i.v.) vancomycin-only therapy, especially in patients who require haemodialysis. If i.v. vancomycin is the favoured therapy against E. meningoseptica meningitis, the addition of ciprofloxacin, linezolid or rifampicin might be an option to effectively treat this difficult-to-treat infection. Further clinical studies are needed to determine the clinical efficacy of these combination regimens for the treatment of E. meningoseptica meningitis.

Original languageEnglish
JournalInternational Journal of Antimicrobial Agents
DOIs
Publication statusAccepted/In press - 2017

Fingerprint

Vancomycin
Bacteremia
Meningitis
Linezolid
Therapeutics
Immunocompromised Host
Low Birth Weight Infant
Rifampin
Ciprofloxacin
Infection
Staphylococcus
PubMed
Renal Dialysis
Databases

Keywords

  • Bacteraemia
  • Combination therapy
  • Elizabethkingia meningoseptica
  • Meningitis
  • Treatment outcome
  • Vancomycin

ASJC Scopus subject areas

  • Microbiology (medical)
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Role of vancomycin in the treatment of bacteraemia and meningitis caused by Elizabethkingia meningoseptica. / Jean, Shio Shin; Hsieh, Tai Chin; Ning, Yong Zhong; Hsueh, Po Ren.

In: International Journal of Antimicrobial Agents, 2017.

Research output: Contribution to journalArticle

@article{b19487d53f804ecf99abc857c0c3169f,
title = "Role of vancomycin in the treatment of bacteraemia and meningitis caused by Elizabethkingia meningoseptica",
abstract = "Elizabethkingia meningoseptica, a Gram-negative pathogen once deemed clinically insignificant, tends to cause infections among low-birth-weight infants and immunocompromised patients. Previously, vancomycin was reported to cure several patients with bacteraemia caused by E. meningoseptica. Nevertheless, some laboratory investigations also showed considerable discordance between in vitro vancomycin susceptibility results obtained by the disk diffusion and broth microdilution methods against clinical E. meningoseptica isolates as determined using the criteria for staphylococci recommended by the Clinical and Laboratory Standards Institute (CLSI). In this review, the PubMed database (1960-2017) was searched for studies that reported mainly cases with E. meningoseptica bacteraemia or meningitis treated with vancomycin alone or with regimens that included vancomycin. In addition, the in vitro synergy between vancomycin and other agents against isolates of E. meningoseptica was reviewed. Elizabethkingia meningoseptica bacteraemia appears not to universally respond to intravenous (i.v.) vancomycin-only therapy, especially in patients who require haemodialysis. If i.v. vancomycin is the favoured therapy against E. meningoseptica meningitis, the addition of ciprofloxacin, linezolid or rifampicin might be an option to effectively treat this difficult-to-treat infection. Further clinical studies are needed to determine the clinical efficacy of these combination regimens for the treatment of E. meningoseptica meningitis.",
keywords = "Bacteraemia, Combination therapy, Elizabethkingia meningoseptica, Meningitis, Treatment outcome, Vancomycin",
author = "Jean, {Shio Shin} and Hsieh, {Tai Chin} and Ning, {Yong Zhong} and Hsueh, {Po Ren}",
year = "2017",
doi = "10.1016/j.ijantimicag.2017.06.021",
language = "English",
journal = "International Journal of Antimicrobial Agents",
issn = "0924-8579",
publisher = "Elsevier",

}

TY - JOUR

T1 - Role of vancomycin in the treatment of bacteraemia and meningitis caused by Elizabethkingia meningoseptica

AU - Jean, Shio Shin

AU - Hsieh, Tai Chin

AU - Ning, Yong Zhong

AU - Hsueh, Po Ren

PY - 2017

Y1 - 2017

N2 - Elizabethkingia meningoseptica, a Gram-negative pathogen once deemed clinically insignificant, tends to cause infections among low-birth-weight infants and immunocompromised patients. Previously, vancomycin was reported to cure several patients with bacteraemia caused by E. meningoseptica. Nevertheless, some laboratory investigations also showed considerable discordance between in vitro vancomycin susceptibility results obtained by the disk diffusion and broth microdilution methods against clinical E. meningoseptica isolates as determined using the criteria for staphylococci recommended by the Clinical and Laboratory Standards Institute (CLSI). In this review, the PubMed database (1960-2017) was searched for studies that reported mainly cases with E. meningoseptica bacteraemia or meningitis treated with vancomycin alone or with regimens that included vancomycin. In addition, the in vitro synergy between vancomycin and other agents against isolates of E. meningoseptica was reviewed. Elizabethkingia meningoseptica bacteraemia appears not to universally respond to intravenous (i.v.) vancomycin-only therapy, especially in patients who require haemodialysis. If i.v. vancomycin is the favoured therapy against E. meningoseptica meningitis, the addition of ciprofloxacin, linezolid or rifampicin might be an option to effectively treat this difficult-to-treat infection. Further clinical studies are needed to determine the clinical efficacy of these combination regimens for the treatment of E. meningoseptica meningitis.

AB - Elizabethkingia meningoseptica, a Gram-negative pathogen once deemed clinically insignificant, tends to cause infections among low-birth-weight infants and immunocompromised patients. Previously, vancomycin was reported to cure several patients with bacteraemia caused by E. meningoseptica. Nevertheless, some laboratory investigations also showed considerable discordance between in vitro vancomycin susceptibility results obtained by the disk diffusion and broth microdilution methods against clinical E. meningoseptica isolates as determined using the criteria for staphylococci recommended by the Clinical and Laboratory Standards Institute (CLSI). In this review, the PubMed database (1960-2017) was searched for studies that reported mainly cases with E. meningoseptica bacteraemia or meningitis treated with vancomycin alone or with regimens that included vancomycin. In addition, the in vitro synergy between vancomycin and other agents against isolates of E. meningoseptica was reviewed. Elizabethkingia meningoseptica bacteraemia appears not to universally respond to intravenous (i.v.) vancomycin-only therapy, especially in patients who require haemodialysis. If i.v. vancomycin is the favoured therapy against E. meningoseptica meningitis, the addition of ciprofloxacin, linezolid or rifampicin might be an option to effectively treat this difficult-to-treat infection. Further clinical studies are needed to determine the clinical efficacy of these combination regimens for the treatment of E. meningoseptica meningitis.

KW - Bacteraemia

KW - Combination therapy

KW - Elizabethkingia meningoseptica

KW - Meningitis

KW - Treatment outcome

KW - Vancomycin

UR - http://www.scopus.com/inward/record.url?scp=85028462676&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028462676&partnerID=8YFLogxK

U2 - 10.1016/j.ijantimicag.2017.06.021

DO - 10.1016/j.ijantimicag.2017.06.021

M3 - Article

AN - SCOPUS:85028462676

JO - International Journal of Antimicrobial Agents

JF - International Journal of Antimicrobial Agents

SN - 0924-8579

ER -